<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168493</url>
  </required_header>
  <id_info>
    <org_study_id>NHMRC D-01</org_study_id>
    <nct_id>NCT00168493</nct_id>
  </id_info>
  <brief_title>The Neurobiology of Depressive Illness</brief_title>
  <official_title>The Neurobiology of Depressive Illness: Causes and Consequences of Altered Brain Monoaminergic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baker Heart Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to determine why patients with depression are at an elevated risk for the development
      of coronary heart disease, and resolve whether the severity of a patient's depression has a
      counterpart in demonstrable abnormalities in brain chemistry. Studies will be completed in 28
      patients with depression; both males and females. Patients will be studied both untreated and
      during administration of a selective serotonin re-uptake inhibitor (SSRI) antidepressant.
      They will be either newly diagnosed with depression, untreated patients suffering a recent
      relapse, or patients seeking to switch from a non-SSRI antidepressant due to non-response.
      The turnover of chemical messengers in the brain will be estimated by high internal jugular
      venous blood sampling and DNA will be isolated and examined from blood cells. Immune function
      will also be assessed. Whole body and cardiac sympathetic nervous activity will be
      determined, as well as microneurographic recording of muscle sympathetic nervous activity.

      It is hypothesised that patients with depression and no existing demonstrable cardiac disease
      demonstrate:

      Alterations in brain monoaminergic neurotransmitter turnover, resulting in sympathetic
      nervous activation and dysregulation of the baroreflex control to both the heart (vagal) and
      muscle vasoconstrictor sympathetic nerves; and Exhibit enhanced platelet reactivity
      predisposing them to thrombogenesis and myocardial ischaemia.

      Therapeutic intervention with an SSRI will modify cardiac sympathetic function, baroreflex
      sensitivity or platelet reactivity in a fashion likely to reduce cardiac risk.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2000</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of sympathetic nervous system activity and its response to treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response to treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>there is no sham or placebo control arm It is a single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidepressants primarily selective serotonin reuptake inhibitors</intervention_name>
    <description>normal clinical dosages used according to clinical response as determined by a psychiatrist</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depression

        Exclusion Criteria:

          -  heart disease diabetes hypertension psychosis significant suicidal risk dementia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray A Esler, MBBS Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker Heart Research Insitute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David A Barton, MBBSFRANZCP</last_name>
    <phone>61393428946</phone>
    <email>david.barton@bigpond.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murray Esler, PhD Fracp</last_name>
    <phone>61385321338</phone>
    <email>Murray.Esler@baker.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker Heart Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Barton, MBBS</last_name>
      <phone>61393428946</phone>
      <email>david.barton@bigpond.com</email>
    </contact>
    <investigator>
      <last_name>David a Barton, m</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr David Barton</name_title>
    <organization>Baker Heart Research Institute</organization>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Cardiac disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

